真实世界中子宫内膜癌的分子异质性:按分期、组织学和分子亚型的生物标志物模式
该回顾性队列研究利用2006至2020年肿瘤研究信息交换网络去标识数据,纳入671例子宫内膜癌患者,描述POLE、MSI、TP53等生物标志物在不同分期、组织学和TCGA分子亚型中的分布。结果显示PTEN(65.9%)、ARID1A(52.0%)和PIK3CA(39.2%)最常见,TP53突变和ERBB2扩增在非子宫内膜样和晚期疾病中更普遍。研究支持将全面分子分型整合到常规实践以细化预后分层并指导生物标志物驱动治疗。
要点
- PTEN、ARID1A和PIK3CA是真实世界子宫内膜癌中最常见的生物标志物。
- TP53突变和ERBB2扩增在非子宫内膜样和晚期肿瘤中更普遍。
- 全面分子分型有助于细化预后分层和指导靶向治疗。
核心结论
- 子宫内膜癌是复杂疾病,在不同组织学、分期和分子亚型间存在显著分子异质性。
- 真实世界数据支持将全面分子分型整合到常规实践以细化预后分层和指导生物标志物驱动治疗。
研究设计与样本
- 回顾性队列研究,使用2006至2020年肿瘤研究信息交换网络去标识临床和肿瘤测序数据。
- 纳入671例确诊子宫内膜癌且至少一种生物标志物(POLE、MSI、TP53、PTEN、PIK3CA、ARID1A、TMB、ESR1、ERBB2突变和ERBB2扩增)有二代测序结果的患者。
- 按组织学、分期和TCGA定义分子亚型分层总结生物标志物患病率。
主要发现
- 队列平均年龄62.4岁,76%为子宫内膜样组织学。
- 最常见生物标志物为PTEN(65.9%)、ARID1A(52.0%)和PIK3CA(39.2%)。
- TP53突变(25.3%)和ERBB2扩增(4.8%)在非子宫内膜样组织学中患病率分别为64.2%和13.2%,在晚期疾病中分别为41.4%和11.2%。
- POLE、PTEN和TMB-high在早期疾病和子宫内膜样组织学中更普遍。
- TCGA分子亚型中,POLE阳性及MSI-H组PTEN、ARID1A和TMB-high患病率高,TP53突变肿瘤ERBB2扩增率最高。
临床怎么用
- 对子宫内膜癌患者进行综合分子分型以识别不同预后亚型。
- 根据组织学、分期和分子亚型评估TP53突变和ERBB2扩增等标志物以指导靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the prevalence and distribution of molecular biomarkers in endometrial cancer across tumor stage, histology, and molecular subtype using real-world data. METHODS: This retrospective cohort study used de-identified clinical and tumor sequencing data from the Oncology Research Information Exchange Network between 2006 and 2020. Patients diagnosed with endometrial cancer and next-generation sequencing results for ≥1 biomarker (POLE, MSI, TP53, PTEN, PIK3CA, ARID1A, TMB, ESR1, ERBB2 (HER2) mutation, and ERBB2 amplification) were included. Biomarker prevalence was summarized and stratified by histology, stage, and The Cancer Genome Atlas (TCGA)-defined molecular subtypes. RESULTS: The study cohort included 671 patients with a mean age of 62.4 years. Most patients (76%) had tumors with endometrioid histology. The most prevalent biomarkers included PTEN (65.9%), ARID1A (52.0%), and PIK3CA (39.2%). TP53 mutations (25.3%) and ERBB2 amplification (4.8%) were more prevalent in non-endometrioid histology (64.2% and 13.2%) and advanced-stage disease (41.4% and 11.2%) than in endometrioid or early-stage tumors. In contrast, POLE, PTEN, and TMB-high were more prevalent in early-stage disease and endometrioid histology. Across TCGA molecular subtypes, distinct biomarker patterns were observed: POLE-positive and MSI-H groups had high PTEN, ARID1A, and TMB-high prevalence, while TP53-mutated tumors showed the highest rates of ERBB2 amplification. CONCLUSIONS: The results of this real-world study demonstrate that endometrial cancer is a complex disease, characterized by substantial molecular heterogeneity and varying biomarker distributions across histology, stages, and molecular subtypes. This real-world study supports the integration of comprehensive molecular profiling into routine practice to refine prognostic stratification and guide biomarker-driven therapies.
引用
- Paranjpe R, Chen C, Sun Y, et al. Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype. Gynecol Oncol. 2026. PMID: 41930527. doi:10.1016/j.ygyno.2026.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。